Alnylam Pharmaceuticals
ALNY
#723
Rank
$23.55 B
Marketcap
$189.74
Share price
-0.36%
Change (1 day)
15.82%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2022 (TTM): -$0.98 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings (TTM) are -$0.98 B. a decrease over its 2021 earnings that were of -$0.71 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2022

Annual earnings

Year Earnings Change
2022-$0.98 B36.93%
2021-$0.71 B-11.32%
2020-$0.8 B-14.88%
2019-$0.94 B15.31%
2018-$0.82 B62.91%
2017-$0.51 B17.78%
2016-$0.43 B43.44%
2015-$0.3 B60.69%
2014-$0.19 B98.2%
2013-$92.95 M
2011-$54.82 M27.48%
2010-$43.01 M-8.52%
2009-$47.01 M90.64%
2008-$24.66 M
2006-$39.51 M-9.13%
2005-$43.48 M34.74%
2004-$32.27 M36.79%
2003-$23.59 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
$8.37 B-962.08%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$11.49 B-1,283.64%๐Ÿ‡ซ๐Ÿ‡ท France
$4.85 B-600.38%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.69 B-28.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-$27.96 M-97.12%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.4 B-59.68%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.14 B 119.97%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
-$0.16 B-83.80%๐Ÿ‡บ๐Ÿ‡ธ USA